The Limited Times

Now you can see non-English news...

Guillain-Barré syndrome listed as a "very rare" side effect of the AstraZeneca vaccine

2021-09-09T04:24:17.270Z


The European Medicines Agency (EMA) on Wednesday listed Guillain-Barré syndrome, a rare neurological impairment, as a side effect ...


The European Medicines Agency (EMA) on Wednesday listed Guillain-Barré syndrome, a rare neurological impairment, as a "

very rare

"

side effect

of AstraZeneca's Covid-19 vaccine.

According to the EMA, 833 cases of the neurological syndrome have been reported worldwide as of July 31, while more than 592 million doses of Vaxzevria serum, from the AstraZeneca laboratory, have been administered worldwide as of July 25. July.

Read alsoCovid-19: 12,828 new cases in 24 hours, 100 deaths in French hospitals

"

The EMA Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that a causal relationship between Vaxzevria and Guillain-Barré syndrome is considered at least a reasonable possibility

," said the European regulator in a press release.

"

Guillain-Barré syndrome should therefore be added to product information as a side effect of Vaxzevria,

" said the agency, headquartered in Amsterdam.

The frequency category assigned is "

very rare

", that is, occurring in less than 1 in 10,000 people.

Read also Jean Castex announces the end of the reimbursement of Covid tests for October 15

Guillain-Barré syndrome is an attack on the peripheral nerves characterized by weakness or even progressive paralysis, most often starting in the legs and sometimes going up to reach the breathing muscles then the nerves of the head and neck. .

The EMA has recommended an update of a warning included since July in the product information to raise awareness of the risks among healthcare professionals and those receiving the vaccine.

The warning also reminds patients to seek medical attention immediately if they develop weakness and paralysis of the extremities that may progress to the chest and face.

The European regulator had listed Guillain-Barré syndrome in July as a "

very rare

"

side effect

of the Johnson & Johnson anti-Covid-19 vaccine, using the same adenovirus technology as the Vaxzevria serum. The US Medicines Agency also warned in July of an "

increased risk

" of developing neurological syndrome with Johnson & Johnson's serum. Both regulators had clarified that the vaccine's benefits outweighed the potential risks.

Source: lefigaro

All news articles on 2021-09-09

You may like

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z
News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.